All In Biotech

Drug Trial Radar · NCT04195399

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

31

Actual

Start

Oct 7, 2020

Primary completion

Mar 31, 2026

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
First posted
Dec 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Desmoid Fibromatosis
  • Recurrent Desmoid Fibromatosis
  • Unresectable Desmoid Fibromatosis

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo ECHO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Nirogacestat HydrobromideDrug

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • X-Ray ImagingProcedure

    Undergo x-ray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Up to 2 years from study entry
  2. Percentage of patients experiencing grade 3+ adverse events (AE)Time frame: Up to 6 years from study entry
  3. Pharmacokinetic (PK) parameter: systemic exposureTime frame: Up to Cycle 3 (each cycle lasts 28 days)
  4. PK parameter: drug clearanceTime frame: Up to Cycle 3 (each cycle lasts 28 days)
  5. PK parameter: half-lifeTime frame: Up to Cycle 3 (each cycle lasts 28 days)

Locations

98 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • USA Health Strada Patient Care Center

    Mobile, Alabama

  • Banner Children's at Desert

    Mesa, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Kaiser Permanente Downey Medical Center

    Downey, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Mattel Children's Hospital UCLA

    Los Angeles, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

    Denver, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Nemours Children's Hospital

    Orlando, Florida

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida

  • Saint Joseph's Hospital/Children's Hospital-Tampa

    Tampa, Florida

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho

  • Lurie Children's Hospital-Chicago

    Chicago, Illinois

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

  • OSF Children's Hospital of Illinois

    Peoria, Illinois

  • Riley Hospital for Children

    Indianapolis, Indiana

  • Norton Children's Hospital

    Louisville, Kentucky

  • Children's Hospital New Orleans

    New Orleans, Louisiana

  • Ochsner Medical Center Jefferson

    New Orleans, Louisiana

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.